Movement Alert｜Guardant Health Pre-Market Rise 5.35%, Bernstein Sees Revenue Upside From ADLT Pricing Qualification

Market Focus07-01 21:23

On July 1, Guardant Health rose 5.35% in pre-market trading, trading near $158.05/share with turnover of approximately $672,000. The rally was driven by a bullish initiation from Bernstein.

Bernstein issued an Outperform rating on the company with a $175 price target, highlighting that G360 ADLT pricing qualification is expected to unlock meaningful revenue upside not yet reflected in consensus estimates. The firm's earnings projections stand 6.6% above consensus for fiscal year 2027 and 12.2% above for 2028. Bernstein also noted that the market significantly underestimates the company's gross margin improvement potential, with the transition to the NovaSeq X platform expected to contribute 350 to 550 basis points of positive impact over the full year.

The upgrade follows a series of positive catalysts in recent months, including FDA approvals for Guardant360 CDx and Guardant360 Liquid CDx as companion diagnostics, inclusion of the Shield blood test in American Cancer Society screening guidelines, and a Q1 earnings beat with revenue guidance raised to $1.30B-$1.32B versus the $1.27B FactSet estimate.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170394378?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-01 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170394378","market":"us","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Pre-Market Rise 5.35%, Bernstein Sees Revenue Upside From ADLT Pricing Qualification","media":"Market Focus","content":"<p><p>On July 1, Guardant Health rose 5.35% in pre-market trading, trading near $158.05/share with turnover of approximately $672,000. The rally was driven by a bullish initiation from Bernstein.</p><p>Bernstein issued an Outperform rating on the company with a $175 price target, highlighting that G360 ADLT pricing qualification is expected to unlock meaningful revenue upside not yet reflected in consensus estimates. The firm's earnings projections stand 6.6% above consensus for fiscal year 2027 and 12.2% above for 2028. Bernstein also noted that the market significantly underestimates the company's gross margin improvement potential, with the transition to the NovaSeq X platform expected to contribute 350 to 550 basis points of positive impact over the full year.</p><p>The upgrade follows a series of positive catalysts in recent months, including FDA approvals for Guardant360 CDx and Guardant360 Liquid CDx as companion diagnostics, inclusion of the Shield blood test in American Cancer Society screening guidelines, and a Q1 earnings beat with revenue guidance raised to $1.30B-$1.32B versus the $1.27B FactSet estimate.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Pre-Market Rise 5.35%, Bernstein Sees Revenue Upside From ADLT Pricing Qualification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Pre-Market Rise 5.35%, Bernstein Sees Revenue Upside From ADLT Pricing Qualification\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-01 21:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 1, Guardant Health rose 5.35% in pre-market trading, trading near $158.05/share with turnover of approximately $672,000. The rally was driven by a bullish initiation from Bernstein.</p><p>Bernstein issued an Outperform rating on the company with a $175 price target, highlighting that G360 ADLT pricing qualification is expected to unlock meaningful revenue upside not yet reflected in consensus estimates. The firm's earnings projections stand 6.6% above consensus for fiscal year 2027 and 12.2% above for 2028. Bernstein also noted that the market significantly underestimates the company's gross margin improvement potential, with the transition to the NovaSeq X platform expected to contribute 350 to 550 basis points of positive impact over the full year.</p><p>The upgrade follows a series of positive catalysts in recent months, including FDA approvals for Guardant360 CDx and Guardant360 Liquid CDx as companion diagnostics, inclusion of the Shield blood test in American Cancer Society screening guidelines, and a Q1 earnings beat with revenue guidance raised to $1.30B-$1.32B versus the $1.27B FactSet estimate.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1170394378","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170394378","pubTimestamp":1782912239,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 1, Guardant Health rose 5.35% in pre-market trading, trading near $158.05/share with turnover of approximately $672,000. The rally was driven by a bullish initiation from Bernstein.Bernstein...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"动向提示|Guardant Health盘前上涨5.35%，Bernstein认为ADLT定价资格带来营收上行空间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On July 1, Guardant Health rose 5.35% in pre-market trading, trading near $158.05/share with turnover of approximately $672,000. The rally was driven by a bullish initiation from Bernstein.Bernstein issued an Outperform rating on the company with a $175 price target, highlighting that G360 ADLT pricing qualification is expected to unlock meaningful revenue upside not yet reflected in consensus estimates. The firm's earnings projections stand 6.6% above consensus for fiscal year 2027 and 12.2% above for 2028. Bernstein also noted that the market significantly underestimates the company's gross margin improvement potential, with the transition to the NovaSeq X platform expected to contribute 350 to 550 basis points of positive impact over the full year.The upgrade follows a series of positive catalysts in recent months, including FDA approvals for Guardant360 CDx and Guardant360 Liquid CDx as companion diagnostics, inclusion of the Shield blood test in American Cancer Society screening guidelines, and a Q1 earnings beat with revenue guidance raised to $1.30B-$1.32B versus the $1.27B FactSet estimate.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170394378","isCrawlerRequest":true}